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Signal transduction: Clamping down on Src activity
Bruce J. Mayer
Recent high-resolution structures of members of the
Src family of protein-tyrosine kinases illustrate how a
series of cooperative intramolecular interactions
represses the catalytic activity of these kinases, but
allows for their rapid activation by a variety of
regulatory inputs.
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The protein-tyrosine kinase Src has played a leading role
in the history of understanding oncogenes, so the recent
description of its three-dimensional structure [1] is a mile-
stone for the fields of cancer research and signal transduc-
tion. It is now almost 90 years since Peyton Rous
demonstrated that an extract from a tumor of a domestic
chicken could induce tumors in other chickens, ushering in
the molecular analysis of cancer. The agent responsible,
later known as Rous sarcoma virus, became the focus of
most of the early studies of retroviral replication and infec-
tivity, and the discovery that the transforming properties of
the virus were due to a single gene, termed src, that origi-
nates from the host genome, confirmed in surprising and
dramatic fashion the genetic basis of cancer. The protein
encoded by the v-src gene was found to be a protein kinase
and soon became the prototype of a class of kinases that
phosphorylate tyrosine residues of substrate proteins. We
now know that protein-tyrosine kinases are intimately
involved in signaling in multicellular organisms, either
serving directly as membrane-bound receptors or coupled
to such receptors in order to integrate responses to a host of
growth factors and other extracellular cues.
The finding that normal cells make c-Src, the unmutated
‘proto-oncogenic’ form of the viral kinase, raised a
fascinating question: how could a well-behaved and pre-
sumably useful kinase be converted into an uncontrolled
oncogenic form? Mutagenesis and biochemical analysis by
a number of groups led to a model in which the c-Src
kinase is held in an inactive conformation by intramolecu-
lar interactions that are regulated by tyrosine phosphoryla-
tion. The recent solutions of the three-dimensional
structures of members of the Src family are entirely
consistent with the existing data, and in that sense are
unsurprising. But what could never be appreciated by
mutagenesis or biochemistry was the elegance of the
design of these kinases, or the subtle interplay of domain
interactions that reins in the activity of the enzyme yet
leaves it poised to spring into action on command. 
The Src family of nonreceptor tyrosine kinases consists of
nine closely related members, each of which contains an
amino-terminal myristoylation site, an amino-terminal
segment specific to the particular member, a Src homology
3 (SH3) domain and an SH2 domain, a catalytic domain,
and a carboxy-terminal tail containing a regulatory tyrosine
phosphorylation site (Fig. 1a) [2]. SH2 and SH3 domains
are found in a wide variety of proteins and are small
modules that mediate protein–protein interactions: SH2
domains bind specifically to tyrosine-phosphorylated
peptides, whereas SH3 domains bind to proline-rich
peptides that adopt the polyproline-II (PP-II) helical
conformation [3,4]. The Src catalytic domain is quite
active when expressed as an individual domain, and
repression of its activity is due to the ‘regulatory appara-
tus’ consisting of the SH2 domain, the SH3 domain, and
the carboxy-terminal tail. 
Many studies suggested that phosphorylation of the
carboxy-terminal regulatory tyrosine residue (Tyr 527 in
chicken c-Src, the prototype of the family) inhibits Src
activity via an intramolecular interaction with the SH2
domain [2]. Somewhat surprisingly, studies in yeast
showed that the SH3 domain was also required for the
inhibition of Src by the SH2–tail interaction [5], although
the precise mechanism was unclear as there is no obvious
proline-rich potential SH3-binding site in the Src protein.
In the cell, regulation of Src is thought to be additionally
mediated by the actions of other enzymes, such as the
tyrosine kinase Csk, which efficiently phosphorylates the
carboxy-terminal regulatory site, and phosphatases that
can dephosphorylate this site. Mutagenic data have also
suggested that the SH2 and SH3 domains can play a posi-
tive role in the active kinase: SH2 and SH3 domain
mutants of v-Src (which is activated at least in part by
elimination of the carboxy-terminal tyrosine phosphoryla-
tion site) are crippled to varying extents, being unable to
phosphorylate substrates involved in transformation with
the efficiency of the ‘wild-type’ v-Src protein. This proba-
bly reflects a role for these domains in localization of the
kinase or in substrate binding.
The three-dimensional structures of the ‘repressed’ forms
of c-Src and its relative Hck, comprising the SH2, SH3
and catalytic domains, as well as the phosphorylated
carboxy-terminal tail, have been solved recently by X-ray
crystallography [1,6], as has the structure of the active form
of the catalytic domain of another Src family member, Lck
[7]. The active Lck domain is phosphorylated not on the
carboxyl terminus, but instead on a site in the catalytic
domain known as the ‘activation segment’. Phosphorylation
of residues in the corresponding loop correlates with the
activation of a wide variety of kinases, including the more
distantly related serine/threonine kinases such as protein
kinase A (PKA) and cyclin-dependent kinase 2 (Cdk2) [8].
So, what do these structures reveal about the all-important
switch between inactive and active forms of kinases?
As expected, in the inactive forms of Src and Hck, the
phosphorylated carboxy-terminal tyrosine is bound to the
SH2 domain, but somewhat surprisingly the SH2 domain
docks onto the ‘back’ of the catalytic domain (Fig. 1b). The
SH3 domain also interacts with the back of the catalytic
domain, in this case largely with the linker segment con-
necting the SH2 domain to the catalytic domain. Unex-
pectedly, this linker (which contains only one or two
proline residues) forms a left-handed PP-II helix and inter-
acts with the normal ligand-binding surface of the SH3
domain. Therefore, in the inactivated form of the kinase,
the ligand-binding surfaces of both the SH2 and the SH3
domains are engaged in intramolecular interactions. By
contrast, access by either ATP or substrate to the catalytic
cleft between the two lobes of the catalytic domain does
not appear to be sterically blocked — in fact, the Hck crys-
tals were prepared in the presence of an ATP analog. 
The arrangement of the domains in the inactive kinase
allows it to be stable and yet at the same time to be
subject to rapid activation by triggers such as
dephosphorylation of the regulatory tail site. The tail–SH2
interaction is quite weak compared with the binding of
the Src SH2 domain to optimal high-affinity ligands [9], so
if this interaction were solely responsible for repressing
kinase activity, frequent dissociation might be expected to
lead to significant spontaneous activation. If, on the other
hand, the SH2–tail interaction were stronger, then the
phosphorylated tail would almost never be available for
dephosphorylation and the kinase could therefore be acti-
vated only very slowly if at all. The function of the SH3
domain seems to be to provide a second weak intramolec-
ular interaction that contributes to the overall stability of
the inactive conformation. This allows the tail periodically
to dissociate from the SH2 domain and to become avail-
able for dephosphorylation without fully unleashing the
catalytic domain. Of course, if the tail is dephosphory-
lated, the SH3–linker interaction must be insufficient to
stably maintain the inactive conformation.
If the SH3–linker interaction is indeed involved in
repressing activity, then interfering with this interaction
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Figure 1
Structure of human c-Src. (a) Domain
structure of Src family kinases. Functional
domains are labeled and color-coded to
correspond with the three-dimensional
structure shown in (b). The locations of the
major tyrosine phosphorylation sites (Y416,
Y527) are indicated above the domain
structure, and the positions of several
mutations known to activate c-Src are
indicated below. The amino-terminal myristoyl
group is represented by a zigzag line. All
amino-acid numbering corresponds to the
positions in chicken c-Src. (b) Three-
dimensional representation of the backbone
structure of human c-Src comprising the SH3,
SH2 and catalytic domains, and the tyrosine-
phosphorylated carboxy-terminal tail (shown
as ball-and-stick model). The positions of the
structural landmarks that are discussed in text
are indicated. The activation segment is not
well defined in the structure, and missing
residues (410–423) are indicated in white.
(The figure was prepared by W. Xu using the
program Insight II.)
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should lead to Src activation. Consistent with this
suggestion, two residues of the so-called ‘RT loop’ of the
SH3 domain are mutated in v-Src relative to its proto-
oncogenic counterpart, and these mutations alone are
sufficient to at least partially activate c-Src [10]. The
crystal structures reveal that these two residues are
involved in specific contacts with the catalytic domain
(see Fig. 1b), suggesting that the v-Src mutations would
destabilize the SH3–catalytic domain interaction. This
issue was directly addressed by a recent study [11] in
which purified Hck, a Src family kinase, was mixed with
the HIV Nef protein, which is known to bind with high
affinity to the SH3 domain of Hck. Addition of Nef
increased Hck kinase activity approximately 50-fold, sug-
gesting that high-affinity ligands for the SH3 domain can
destabilize the repressed conformation. In fact, Nef was
more potent than SH2 ligands in activating the kinase,
and it could further activate a kinase lacking the regula-
tory carboxy-terminal phosphorylation, suggesting that the
SH3–catalytic domain interaction is in fact more important
than the SH2–tail interaction for maintaining the
repressed conformation.
Like a rolled-up armadillo, the inactive form of the kinase
presents an inert surface to the environment, with the
ligand-binding sites of its SH2 and SH3 domains and the
regulatory phosphorylation site tucked inside, and the cat-
alytic domain held in an inactive conformation. The weak-
ness of the individual interactions, however, allows the
various regulatory trigger points to become momentarily
accessible over time as the structure ‘breathes’. The coop-
erativity of the interactions means that a single activating
input — dephosphorylation of the tail, or engagement of
the SH2 or SH3 domain by high-affinity ligands —
destabilizes the inactive structure and exposes the other
trigger points, leading to further activation of the kinase.
The increased accessibility to ligand of the SH3 domain of
Hck when the SH2–tail interaction is disrupted [11]
provides direct evidence for such cooperativity.
But how do these intramolecular interactions regulate the
activity of the catalytic domain? Here, a comparison with
the active Lck catalytic domain is informative. Protein
kinase catalytic domains consist of two lobes, with the cat-
alytic site located in a cleft between them. Comparison of
a number of kinase structures reveals that a major differ-
ence between inactive and active kinases appears to be
the conformation of the activation segment and a helix in
the amino-terminal lobe termed the ‘C helix’ (see Fig. 1b)
[8]. Activation usually involves phosphorylation of a site in
the activation segment — in the case of Src, Tyr 416 —
and this site is indeed phosphorylated in the structure of
the active Lck catalytic domain. An important
consequence of this phosphorylation in the case of Src
family kinases appears to be rotation of the C helix and
alignment of a glutamate residue on the helix so that it can
interact with Lys295 and assist in the positioning of this
residue, which is important in coordinating the phosphate
groups of ATP [7]; in the repressed structures of Src and
Hck, this glutamate projects into the solvent [1,6].
Remarkably, an identical change in the orientation of the
C helix is involved in the activation of Cdk2 by cyclin
binding [12].
Of course, this finding merely pushes the question of
regulation back one step — how does binding of the SH2
and SH3 domains prevent the phosphorylation of Tyr416
and adoption of the active conformation? Somewhat surpris-
ingly, the structures do not reveal an obvious mechanism
for this aspect of Src regulation. Kuriyan and colleagues [6]
propose that a hydrophobic residue in the SH2–catalytic
domain linker, Trp260, prevents the C helix from assuming
its active ‘inner’ conformation if the SH3 domain is
engaged. Eck and colleagues [1] favor a model in which the
clamping of the SH2 and SH3 domains onto the back of the
catalytic domain in effect paralyzes this domain, preventing
the relative movement of the two lobes which is thought to
be required for the catalytic cycle.
A number of intriguing questions remain. The first of these
concerns the role of phosphorylation of the activation
segment. The studies by Miller and colleagues [11] suggest
that, for the repressed Hck kinase, phosphorylation of
Tyr416 is slow and dependent on the concentration of the
kinase, and that it correlates closely with increased kinase
activity. This is consistent with a model in which a
repressed kinase molecule can, albeit inefficiently, phos-
phorylate the activation segment of a second molecule and
thereby destabilize the inactive conformation of this second
molecule. This model implies that activation could be stim-
ulated by high local concentrations of kinase, in agreement
with the finding that aggregation triggers the activation of
Src family kinases in vivo (as in the activation of Lck by
clustering of T cell receptors). But what happens if the
intramolecular SH2 or SH3 interactions are disrupted?
Autophosphorylation of Hck in the presence of Nef is very
rapid, suggesting that an intramolecular reaction occurs [11].
Although it remains to be proven, this suggests that one role
of the interactions of the SH2 and SH3 domains with the
catalytic domain might be to prevent self-activation by
intramolecular autophosphorylation.
It is clear, however, that autophosphorylation does not
provide the whole story of Src kinase activation — Miller’s
group [11] showed that a prephosphorylated form of Hck,
which was already phosphorylated on the activation
segment, could be further activated by Nef. Therefore,
when the SH2 and SH3 domains are bound to the catalytic
domain, the geometry of the catalytic site or the flexibility
of the two lobes must still be compromised even when
Tyr416 is phosphorylated. It therefore seems likely that
phosphorylation of the catalytic site is a third component
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of the interconnected network of cooperative interactions
that distinguishes between the active and inactive forms
of the kinase — this phosphorylation is insufficient in
itself to activate the kinase fully, but it is able to predis-
pose the kinase to further activation by destabilizing the
repressed conformation.
The chinks in the armor of the repressed kinase are also
apparent in the mutations that occur naturally in v-Src. As
a result of decades of passage in a retrovirus under con-
stant selective pressure to cause the most transforming
phenotypes, v-Src has evolved to be extremely active. All
strains of v-Src have mutations in the carboxy-terminal tail
(almost certainly the first activating mutation, occurring at
the time the src gene was transduced by the retrovirus),
the RT loop of the SH3 domain, and the catalytic domain.
The SH3 mutations presumably disrupt its interaction
with the catalytic domain, as mentioned above; the
catalytic domain mutation (Thr338→Ile) lies within the
hinge region between the two lobes and presumably
destabilizes the inactive conformation of the catalytic site.
So, all three components of the inactivating switch have
been targeted in v-Src. It is also intriguing that two spon-
taneous activated mutants of c-Src each have a single
amino-acid change in the same region of the carboxy-
terminal lobe of the catalytic domain [13]. The location of
these mutations suggests that they might destabilize both
the binding of the carboxy-terminal tail to the SH2
domain [6] and the inactive conformation of the catalytic
domain [1], thereby simultaneously hitting two of the
three activation triggers.
Further enzymatic and structural studies should now
rapidly lead to a fuller understanding of the role of the
individual interactions in triggering the global
conformational changes involved in activation of the Src
family kinases. It will be important to determine the
catalytic activity of different forms of the kinase, which
have different phosphorylation states and different
intramolecular interactions, as well as the equilibria
between these various states in the cell. Mutant forms of
the kinase in which the intramolecular interactions are
artificially strengthened or weakened by site-directed
mutagenesis will help to address these issues. Solving the
structures of different phosphorylated forms of the
kinase, such as Tyr416–P and Tyr527–P, or structures of
the kinase in the presence of activators, such as high-
affinity SH2 or SH3 ligands, will also help to pinpoint the
precise mechanisms of activation. Because Src family
kinases are involved in responses to a variety of important
signals, there is hope that these further studies could lead
to the design of clinically useful modulators of Src kinase
activity.
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